H.C. Wainwright analyst Joseph Pantginis upgraded BerGenBio to Buy from Neutral with a NOK 30 price target. "Now is an opportune time to step off the sidelines with BerGenBio, with its clear focus and strategy in place for bemcentinib," Pantginis tells investors in a research note.
Published first on TheFly
